Monitoring Response to Therapeutic Interventions in Patients With Cancer

Seminars in Nuclear Medicine

Volumn 39, Issue 3, 2009, Pages 210-232

  Herrmann, Ken ^a   Krause, Bernd Joachim ^a   Bundschuh, Ralph A ^a   Dechow, Tobias ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; BLEOMYCIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUORO 3' DEOXY THYMIDINE F 18; FLUORO AZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; GALACTO ARGININE GLYCINE ASPARTIC ACID F 18; GEFITINIB; IMATINIB; LAPATINIB; PREDNISONE; PROCARBAZINE; RADIOPHARMACEUTICAL AGENT; SORAFENIB; UNCLASSIFIED DRUG; VINCRISTINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; IMAGE ENHANCEMENT; LUNG CANCER; MELANOMA; OVARY CANCER; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SARCOMA; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

CELL HYPOXIA; CHEMOTHERAPY, ADJUVANT; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYMIDINE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 63049099054     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2008.12.001     Document Type: Review

References (187)

1. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
2. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
3. Therasse P., Eisenhauer E.A., and Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 42 (2006) 1031-1039
4. Weber W.A. Positron emission tomography as an imaging biomarker. J Clin Oncol 24 (2006) 3282-3292
5. Weber W.A., and Figlin R. Monitoring cancer treatment with PET/CT: Does it make a difference?. J Nucl Med 48 suppl 1 (2007) 36S-44S
6. Weber W.A., Czernin J., Phelps M.E., et al. Technology insight: Novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol 5 (2008) 44-54
7. Hellwig D., Graeter T.P., Ukena D., et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 128 (2004) 892-899
8. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
9. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21 (2003) 2651-2657
10. Wieder H.A., Beer A.J., Lordick F., et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 46 (2005) 2029-2034
11. Weber W.A., and Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 33 suppl 1 (2006) 27-37
12. Beyer T., Townsend D.W., Brun T., et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 41 (2000) 1369-1379
13. Delbeke D., Coleman R.E., Guiberteau M.J., et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 47 (2006) 885-895
14. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999) 1773-1782
15. Shankar L.K., Hoffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47 (2006) 1059-1066
16. Park K.W., Ashlock R., Chang W.B., et al. High variation in standardized uptake values among PET systems from different manufacturers. J Nucl Med Meeting Abstracts 48 (2007) 185P-a
17. Beyer T., Antoch G., Muller S., et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 45 suppl 1 (2004) 25S-35S
18. Nehmeh S.A., Erdi Y.E., Pan T., et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 31 (2004) 3179-3186
19. Pan T., Mawlawi O., Nehmeh S.A., et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46 (2005) 1481-1487
20. Bundschuh R.A., Martinez-Moller A., Essler M., et al. Local motion correction for lung tumours in PET/CT-first results. Eur J Nucl Med Mol Imaging 35 (2008) 1981-1988
21. Kinahan P.E., Hasegawa B.H., and Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 33 (2003) 166-179
22. Antoch G., Freudenberg L.S., Beyer T., et al. To enhance or not to enhance?. 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 45 suppl 1 (2004) 56S-65S
23. Bundschuh R.A., Martinez-Moller A., Ziegler S.I., et al. Misalignment in PET/CT: relevance for SUV and therapy management. Nuklearmedizin 47 (2008) N14-N15
24. Mamede M., Higashi T., Kitaichi M., et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7 (2005) 369-379
25. de Geus-Oei L.F., van Krieken J.H., Aliredjo R.P., et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55 (2007) 79-87
26. Yen T.C., See L.C., Lai C.H., et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 45 (2004) 22-29
27. Westerterp M., Sloof G.W., Hoekstra O.S., et al. 18FDG uptake in oesophageal adenocarcinoma: Linking biology and outcome. J Cancer Res Clin Oncol 134 (2008) 227-236
28. Buerkle A., and Weber W.A. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 27 (2008) 545-554
29. Cullinane C., Dorow D.S., Kansara M., et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 65 (2005) 9633-9636
30. Wahl R.L., Cody R.L., Hutchins G.D., et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179 (1991) 765-770
31. Zasadny K.R., and Wahl R.L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 189 (1993) 847-850
32. Kim C.K., Gupta N.C., Chandramouli B., et al. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 35 (1994) 164-167
33. Lammertsma A.A., Hoekstra C.J., Giaccone G., et al. How should we analyse FDG PET studies for monitoring tumour response?. Eur J Nucl Med Mol Imaging 33 suppl 1 (2006) 16-21
34. Hoekstra C.J., Hoekstra O.S., Stroobants S.G., et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43 (2002) 1304-1309
35. Leskinen-Kallio S., Nagren K., Lehikoinen P., et al. Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med 33 (1992) 691-695
36. Weber W.A., Ziegler S.I., Thodtmann R., et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40 (1999) 1771-1777
37. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 18 (2000) 3495-3502
38. Avril N., Sassen S., Schmalfeldt B., et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 23 (2005) 7445-7453
39. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol 21 (2003) 4604-4610
40. Ott K, Weber WA, Lordick F, et al: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24:4692-4698
41. Ott K., Herrmann K., Lordick F., et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14 (2008) 2012-2018
42. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
43. Wieder H.A., Brucher B.L., Zimmermann F., et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22 (2004) 900-908
44. Benz M.R., Evilevitch V., len-Auerbach M.S., et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: Interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 49 (2008) 1038-1046
45. Weinberg I.N., Huang S.C., Hoffman E.J., et al. Validation of PET-acquired input functions for cardiac studies. J Nucl Med 29 (1988) 241-247
46. Hoekstra C.J., Hoekstra O.S., and Lammertsma A.A. On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies. Eur J Nucl Med 26 (1999) 1489-1492
47. Graham M.M., Peterson L.M., and Hayward R.M. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 27 (2000) 647-655
48. Patlak C.S., Blasberg R.G., and Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3 (1983) 1-7
49. Alkhawaldeh K., Bural G., Kumar R., et al. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 35 (2008) 246-252
50. Matthies A., Hickeson M., Cuchiara A., et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43 (2002) 871-875
51. Hoffman E.J., Huang S.C., and Phelps M.E. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 3 (1979) 299-308
52. Soret M., Bacharach S.L., and Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 48 (2007) 932-945
53. Rousset O., Rahmim A., Alavi A., et al. Partial volume correction strategies in PET. PET Clinics 2 (2007) 235-249
54. Pottgen C., Levegrun S., Theegarten D., et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12 (2006) 97-106
55. Hickeson M., Yun M., Matthies A., et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 29 (2002) 1639-1647
56. Becker K., Mueller J.D., Schulmacher C., et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98 (2003) 1521-1530
57. Prentice R.L. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8 (1989) 431-440
58. Flamen P., Van C.E., Lerut A., Cambier J.P., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 (2002) 361-368
59. Diehl V., and Fuchs M. Early, intermediate and advanced Hodgkin's lymphoma: Modern treatment strategies. Ann Oncol 18 suppl 9 (2007) ix71-ix79
60. Schmits R., Schmitz N., and Pfreundschuh M. The best treatment for diffuse large B-cell lymphoma: a German perspective. Oncology (Williston Park) 19 suppl 4 (2005) 16-25
61. Franklin J., Pluetschow A., Paus M., et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 17 (2006) 1749-1760
62. Diehl V., and Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?. Cancer Invest 24 (2006) 461-465
63. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
64. Facey K., Bradbury I., Laking G., et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11 44 (2007) iii-267
65. Gallamini A., Rigacci L., Merli F., et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 91 (2006) 475-481
66. Haioun C., Itti E., Rahmouni A., et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
67. Hutchings M., Eigtved A.I., and Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 52 (2004) 19-32
68. Hutchings M., Loft A., Hansen M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
69. Jerusalem G., Beguin Y., Fassotte M.F., et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85 (2000) 613-618
70. Juweid M.E., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 (2005) 4652-4661
71. Kostakoglu L., Goldsmith S.J., Leonard J.P., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107 (2006) 2678-2687
72. Mikhaeel N.G., Hutchings M., Fields P.A., et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 (2005) 1514-1523
73. Romer W., Hanauske A.R., Ziegler S., et al. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91 (1998) 4464-4471
74. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
75. Seam P., Juweid M.E., and Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood 110 10 (2007) 3507-3516 Nov 15
76. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 104 (2004) 1258-1265
77. Spaepen K., Stroobants S., Dupont P., et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13 (2002) 1356-1363
78. Terasawa T., Nihashi T., Hotta T., et al. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: A systematic review. J Nucl Med 49 (2008) 13-21
79. Zinzani P.L., Tani M., Fanti S., et al. Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol 17 (2006) 1296-1300
80. Fletcher J.W., Djulbegovic B., Soares H.P., et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49 (2008) 480-508
81. Kobe C., Dietlein M., Franklin J., et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112 (2008) 3989-3994
82. Jemal A., Travis W.D., Tarone R.E., et al. Lung cancer rates convergence in young men and women in the United States: Analysis by birth cohort and histologic type. Int J Cancer 105 (2003) 101-107
83. Pirker R., Szczesna A., Von P.J., et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol suppl (2008) 26
84. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
85. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
86. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
87. Hoekstra C.J., Stroobants S.G., Smit E.F., et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 8362-8370
88. de Geus-Oei L.F., van der Heijden H.F., Visser E.P., et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 48 (2007) 1592-1598
89. Dooms C., Verbeken E., Stroobants S., et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 26 (2008) 1128-1134
90. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
91. Gebski V., Burmeister B., Smithers B.M., et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8 (2007) 226-234
92. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 8 (2007) 797-805
93. Gillham C.M., Lucey J.A., Keogan M., et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 95 (2006) 1174-1179
94. Brucher B.L., Weber W., Bauer M., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg 233 (2001) 300-309
95. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 21 (2003) 428-432
96. Kim M.K., Ryu J.S., Kim S.B., et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43 (2007) 1385-1391
97. Port J.L., Lee P.C., Korst R.J., et al. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 84 (2007) 393-400 Aug
98. Swisher S.G., Maish M., Erasmus J.J., et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78 (2004) 1152-1160
99. Smithers B.M., Couper G.C., Thomas J.M., et al. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus 21 (2008) 151-158
100. Lordick F., Ruers T., Aust D.E., et al. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 44 (2008) 1807-1819
101. Ott K., Lordick F., Herrmann K., et al. The new credo: induction chemotherapy in locally advanced gastric cancer: Consequences for surgical strategies. Gastric Cancer 11 (2008) 1-9
102. Roder J.D., Bottcher K., Siewert J.R., et al. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 72 (1993) 2089-2097
103. Shah M.A., Yeung H.W., Coit D., et al. A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET/CT predicts patient outcome. (abstr). J Clin Oncol 25 (2007) 4502
104. Herrmann K., Ott K., Buck A.K., et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: A comparative analysis. J Nucl Med 48 (2007) 1945-1950
105. Krebs in Deutschland, Häufigkeiten und Trends (2008), Robert Koch-Institut, Berlin, Germany 34-37
106. Calvo F.A., Domper M., Matute R., et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 58 (2004) 528-535
107. Cascini G.L., Avallone A., Delrio P., et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 47 (2006) 1241-1248
108. de Geus-Oei L.F., van Laarhoven H.W., Visser E.P., et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 19 (2008) 348-352
109. Findlay M., Young H., Cunningham D., et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 14 (1996) 700-708
110. Funaioli C., Pinto C., Di F.F., et al. 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy. Tumori 93 (2007) 611-615
111. Guillem J.G., Moore H.G., Akhurst T., et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 199 (2004) 1-7
112. Rosenberg R., Herrmann K., Gertler R., et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 24 (2009) 191-200
113. Kelly H., and Goldberg R.M. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23 (2005) 4553-4560
114. Chia S., Swain S.M., Byrd D.R., et al. Locally advanced and inflammatory breast cancer. J Clin Oncol 26 (2008) 786-790
115. Gralow J.R., Zujewski J.A., and Winer E. Preoperative therapy in invasive breast cancer: Reviewing the state of the science and exploring new research directions. J Clin Oncol 26 (2008) 696-697
116. Gralow J., Ozols R.F., Bajorin D.F., et al. Clinical cancer advances 2007: Major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 26 (2008) 313-325
117. Wahl R.L., Zasadny K., Helvie M., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11 (1993) 2101-2111
118. Schelling M., Avril N., Nahrig J., et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18 (2000) 1689-1695
119. Smith I.C., Welch A.E., Hutcheon A.W., et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18 (2000) 1676-1688
120. Couturier O., Jerusalem G., N′Guyen J.M., et al. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 12 (2006) 6437-6443
121. Dose S.J., Bader M., Jenicke L., et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46 (2005) 1144-1150
122. Gennari A., Donati S., Salvadori B., et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 1 (2000) 156-161
123. Grigsby P.W., Siegel B.A., Dehdashti F., et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 22 (2004) 2167-2171
124. Schwarz J.K., Siegel B.A., Dehdashti F., et al. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298 (2007) 2289-2295
125. Nishiyama Y., Yamamoto Y., Kanenishi K., et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging 35 (2008) 287-295
126. Strobel K., Dummer R., Steinert H.C., et al. Chemotherapy response assessment in stage IV melanoma patients-comparison of (18)F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging 35 (2008) 1786-1795
127. Strobel K., Skalsky J., Steinert H.C., et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology 215 (2007) 192-201
128. Brun E., Kjellen E., Tennvall J., et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24 (2002) 127-135
129. Kunkel M., Forster G.J., Reichert T.E., et al. Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 39 (2003) 170-177
130. Connell C.A., Corry J., Milner A.D., et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 29 (2007) 986-995
131. Stroobants S., Goeminne J., Seegers M., et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39 (2003) 2012-2020
132. Gayed I., Vu T., Iyer R., et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45 (2004) 17-21
133. Antoch G., Kanja J., Bauer S., et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45 (2004) 357-365
134. Goerres G.W., Stupp R., Barghouth G., et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: Long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32 (2005) 153-162
135. Holdsworth C.H., Badawi R.D., Manola J.B., et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 189 (2007) W324-W330
136. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 (2007) 1753-1759
137. Schulte M., Brecht-Krauss D., Werner M., et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 40 (1999) 1637-1643
138. Schuetze S.M., Rubin B.P., Vernon C., et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103 (2005) 339-348
139. Jones D.N., McCowage G.B., Sostman H.D., et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37 (1996) 1438-1444
140. Hawkins D.S., Schuetze S.M., Butrynski J.E., et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23 (2005) 8828-8834
141. Hawkins D.S., Rajendran J.G., Conrad E.U., et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 94 (2002) 3277-3284
142. Franzius C., Drup-Link H.E., Sciuk J., et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: Comparison with spiral CT. Ann Oncol 12 (2001) 479-486
143. Franzius C., Sciuk J., Brinkschmidt C., et al. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 25 (2000) 874-881
144. Evilevitch V., Weber W.A., Tap W.D., et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14 (2008) 715-720
145. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
146. Shreve P.D., Anzai Y., and Wahl R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19 (1999) 61-77
147. Kubota R., Kubota K., Yamada S., et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 35 (1994) 104-112
148. Wells P., Gunn R.N., Alison M., et al. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 62 (2002) 5698-5702
149. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
150. 18F]FLT). J Radioanal Nucl Chem 243 (2000) 843-846
151. Rasey J.S., Grierson J.R., Wiens L.W., et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43 (2002) 1210-1217
152. Barthel H., Perumal M., Latigo J., et al. The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32 (2005) 257-263
153. Wagner M., Seitz U., Buck A., et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 63 (2003) 2681-2687
154. Perumal M., Pillai R.G., Barthel H., et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 66 (2006) 8558-8564
155. Been L.B., Elsinga P.H., de Vries J., et al. Positron emission tomography in patients with breast cancer using (18)F-3′-deoxy-3′-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 32 (2006) 39-43
156. Smyczek-Gargya B., Fersis N., Dittmann H., et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study. Eur J Nucl Med Mol Imaging 31 5 (2004) 720-724
157. van Westreenen H.L., Cobben D.C., Jager P.L., et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 46 (2005) 400-404
158. Francis D.L., Visvikis D., Costa D.C., et al. Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 3 (2003) 988-994
159. Herrmann K., Eckel F., Schmidt S., et al. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. J Nucl Med 49 (2008) 1437-1444
160. Buck A.K., Hetzel M., Schirrmeister H., et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 32 (2005) 525-533
161. Dittmann H., Dohmen B.M., Paulsen F., et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 30 10 (2003) 1407-1412
162. Tian J., Yang X., Yu L., et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med 49 (2008) 186-194
163. Yamamoto Y., Nishiyama Y., Ishikawa S., et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34 (2007) 1610-1616
164. Yap C.S., Czernin J., Fishbein M.C., et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 129 (2006) 393-401
165. Chen W., Cloughesy T., Kamdar N., et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46 (2005) 945-952
166. Choi S.J., Kim J.S., Kim J.H., et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 32 (2005) 653-659
167. Cobben D.C., Jager P.L., Elsinga P.H., et al. 3′-18F-fluoro-3′-deoxy-L-thymidine: A new tracer for staging metastatic melanoma?. J Nucl Med 44 (2003) 1927-1932
168. Cobben D.C., van der Laan B.F., Maas B., et al. 18F-FLT PET for visualization of laryngeal cancer: Comparison with 18F-FDG PET. J Nucl Med 45 (2004) 226-231
169. Troost E.G., Vogel W.V., Merkx M.A., et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48 (2007) 726-735
170. Buck A.K., Herrmann K., Buschenfelde C.M., et al. Imaging bone and soft tissue tumors with the proliferation marker [18F]Fluorodeoxythymidine. Clin Cancer Res 14 (2008) 2970-2977
171. Cobben D.C., Elsinga P.H., Suurmeijer A.J., et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-L-thymidine. Clin Cancer Res 10 (2004) 1685-1690
172. Salskov A., Tammisetti V.S., Grierson J., et al. FLT: Measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Semin Nucl Med 37 (2007) 429-439
173. Pio B.S., Park C.K., Pietras R., et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8 (2006) 36-42
174. Kenny L., Coombes R.C., Vigushin D.M., et al. Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34 (2007) 1339-1347
175. Herrmann K., Wieder H.A., Buck A.K., et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13 (2007) 3552-3558
176. Chen W., Delaloye S., Silverman D.H., et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 25 30 (2007) 4714-4721
177. Been L.B., Suurmeijer A.J., Elsinga P.H., et al. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med 48 (2007) 367-372
178. Grierson J.R., Link J.M., Mathis C.A., et al. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 30 (1989) 343-350
179. Krause B.J., Beck R., Souvatzoglou M., and Piert M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 50 (2006) 28-43 Mar
180. Lee S.T., and Scott A.M. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 37 (2007) 451-461
181. Gronroos T., Eskola O., Lehtio K., et al. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 42 (2001) 1397-1404
182. Yang D.J., Wallace S., Cherif A., et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 194 (1995) 795-800
183. Souvatzoglou M., Grosu A.L., Roper B., et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: A pilot study. Eur J Nucl Med Mol Imaging 34 (2007) 1566-1575
184. Rajendran J.G., Wilson D.C., Conrad E.U., et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30 (2003) 695-704
185. Koh W.J., Bergman K.S., Rasey J.S., et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33 (1995) 391-398
186. Hicks R.J., Rischin D., Fisher R., et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32 (2005) 1384-1391
187. Gagel B., Reinartz P., Demirel C., et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6 (2006) 51